Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
EIF2B5
REST API REST API
Homo sapiens
EIF2B5 is differentially expressed in 231 experiments: 89 organism parts: trigeminal ganglion, mammary gland, ... (87 more);, 135 disease states: normal, acute myeloid leukemia, ... (133 more);, 68 cell types 288 cell lines 73 compound treatments and 51 other conditions.
Synonyms EIF-2B, EIF2Bepsilon
Orthologs GCD6 (Saccharomyces cerevisiae)   EIF2B5 (Bos taurus)   eif2b5 (Danio rerio)   Eif2b5 (Rattus norvegicus)   ENSCING00000000067 (Ciona intestinalis)   ENSCING00000014650 (Ciona intestinalis)   Eif2b5 (Mus musculus)   EIF2B5 (Gallus gallus)   eIF2B-epsilon (Drosophila melanogaster)   eif2b5 (Xenopus tropicalis)   EIF2B5 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, cytoplasm, translation initiation factor binding, RNA metabolic process, response to stress, cellular protein metabolic process, regulation of translation, translation, guanyl-nucleotide exchange factor activity, eukaryotic translation initiation factor 2B complex, translational initiation, nucleus, translation initiation factor activity, transferase activity, binding, response to heat, myelination, cellular response to stimulus, gene expression, astrocyte differentiation, ovarian follicle development, response to peptide hormone stimulus, negative regulation of translational initiation in response to stress, astrocyte development, positive regulation of translational initiation, oligodendrocyte development, response to glucose stimulus
UniProt Accession Q13144, C9JRD9, Q59HD8, E9PC74
Gene-Disease Assocation LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER; VWM
InterPro Term eIF4-gamma/eIF5/eIF2-epsilon
Search EB-eye ENSG00000145191
Show more properties
Experimental Factors
organism part

studied in E-AFMX-5, E-GEOD-13911, E-GEOD-1577, E-GEOD-7540, E-GEOD-6919, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

cell line

studied in E-GEOD-17482, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, E-GEOD-15240, ... (40 experiments)

Factor Value U/D Experiments
HL-60
4
E-MTAB-37, E-GEOD-5258, E-GEOD-995, E-GEOD-24147
T47D
4
E-MEXP-440, E-GEOD-3529, E-MTAB-62, E-GEOD-10890
HT1080
3
E-GEOD-13548, E-MTAB-37, E-GEOD-20089
MDAMB453
3
E-MTAB-37, E-GEOD-10890, E-MTAB-62
SKBR3
3
E-MEXP-440, E-MTAB-62, E-GEOD-10890
SW480
3
E-GEOD-18005, E-MTAB-62, E-GEOD-2509
282 more value(s).


cell type

studied in E-GEOD-3920, E-MEXP-750, E-GEOD-34309, E-GEOD-20677, E-GEOD-23806, ... (40 experiments)

Factor Value U/D Experiments
CD4-positive T cell
1
4
E-MTAB-24, E-GEOD-16190, E-MTAB-25, E-TABM-145, E-AFMX-5 ... (5 experiments)
CD8+ T cell
3
E-MTAB-25, E-TABM-145, E-AFMX-5
T cell
3
E-GEOD-16190, E-GEOD-13987, E-GEOD-6053
CD34+
2
E-TABM-145, E-AFMX-5
epithelial cell
1
E-GEOD-20758
chondrocyte
1
E-TABM-130
62 more value(s).


disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-25, E-GEOD-15960, E-GEOD-1577, ... (48 experiments)

Factor Value U/D Experiments
normal
9
13
E-GEOD-18842, E-TABM-276, E-GEOD-14924, E-GEOD-935, E-GEOD-3365, ... (22 experiments)
acute lymphoblastic leukemia
2
E-GEOD-5824, E-MTAB-37
breast cancer
2
E-MTAB-62, E-GEOD-7307
colorectal adenocarcinoma
2
E-MTAB-37, E-MTAB-62
control
2
E-GEOD-21912, E-GEOD-8121
non-small cell lung cancer
2
E-GEOD-18842, E-MTAB-62
129 more value(s).


Compound treatment

studied in E-MEXP-1601, E-GEOD-10313, E-MTAB-798, E-TABM-782, E-GEOD-697, ... (24 experiments)

Factor Value U/D Experiments
none
5
12
E-GEOD-11462, E-GEOD-19519, E-GEOD-5824, E-MEXP-1601, E-GEOD-10313, ... (17 experiments)
ibuprofen 30 micromolar
1
E-MTAB-798
naproxen 120 micromolar
1
E-MTAB-798
penicillamine 2000 micromolar
1
E-MTAB-798
acetamidofluorene 10 micromolar
1
E-MTAB-798
diltiazem 30 micromolar
1
E-MTAB-798
67 more value(s).


RNAi

studied in E-MEXP-2759, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697 ... (5 experiments)

Factor Value U/D Experiments
HDAC1 knockdown
1
E-GEOD-12438
non-targeting�control siRNA
1
E-MEXP-2759
SIM2s
1
E-MEXP-101
HSF1 siRNA #2
1
E-GEOD-3697
FLI1 siRNA
1
E-MEXP-2759
shZBTB4
1
E-MEXP-1509
2 more value(s).


biosource provider
studied in E-MTAB-37, E-GEOD-19466, E-GEOD-20559, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

cellular component
studied in E-GEOD-1400

chromosomal aberration
studied in E-TABM-125

clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-9489, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-14359, E-GEOD-21589, E-GEOD-13355, ... (6 experiments)

clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-18290

disease stage
studied in E-GEOD-7463

disease staging
studied in E-GEOD-19743, E-GEOD-2509, E-GEOD-22148, E-TABM-147, E-GEOD-3013 ... (5 experiments)

estrogen receptor status
studied in E-GEOD-6532

ethnicity
studied in E-GEOD-1643

genetic modification
studied in E-GEOD-8023, E-GEOD-20847

genotype
studied in E-GEOD-17476, E-GEOD-13911, E-GEOD-8141, E-GEOD-17347, E-GEOD-19293, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

growth condition
studied in E-TABM-263, E-GEOD-6432, E-MEXP-1446, E-GEOD-19864

histology
studied in E-TABM-234, E-GEOD-9489, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (26 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-20948, E-MEXP-561

injury
studied in E-GEOD-19743

irradiate
studied in E-GEOD-1977

ki67 ihc
studied in E-GEOD-21653

labeling
studied in E-LGCL-5

light
studied in E-GEOD-1725

material type
studied in E-MEXP-958, E-MEXP-1082, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

molecular subtype
studied in E-GEOD-21653

organism
studied in E-AFMX-1, E-GEOD-426

organism status
studied in E-GEOD-19188

performer
studied in E-LGCL-5

phenotype
studied in E-GEOD-12355, E-GEOD-21750, E-GEOD-1460, E-GEOD-5824, E-GEOD-26541 ... (5 experiments)

progesterone receptor status
studied in E-GEOD-6532

protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19249, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

read length
studied in E-GEOD-30222

sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

sampling time point
studied in E-GEOD-16797, E-MTAB-798

sex
studied in E-GEOD-7307

shRNA expression
studied in E-GEOD-33816

stimulus
studied in E-GEOD-22103

subtype
studied in E-GEOD-24283

survival time
studied in E-GEOD-19188

test result
studied in E-GEOD-1926, E-TABM-276

treatment
studied in E-GEOD-34055, E-GEOD-19246, E-GEOD-12198

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.861 secs.
 
Gene Expression Atlas 2.0.13- 4/23/12 11:55:46 AM